Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,345,700 | 2,885,600 | 3,432,400 | 2,072,200 | 1,437,900 |
| Marketable Securities | 3,704,900 | 2,809,100 | 2,355,200 | 1,838,600 | 2,065,900 |
| Receivables | 4,839,000 | 6,036,500 | 5,452,000 | 6,998,600 | 4,173,000 |
| Inventories | 1,991,500 | 1,951,300 | 2,053,800 | 1,983,900 | 2,164,700 |
| TOTAL | $14,306,000 | $14,014,900 | $13,775,400 | $13,337,600 | $10,055,100 |
| Non-Current Assets | |||||
| PPE Net | 3,556,400 | 3,482,200 | 3,395,700 | 3,358,500 | 3,262,600 |
| Investments And Advances | 7,084,000 | 6,838,000 | 5,631,300 | 3,900,300 | 3,543,700 |
| Intangibles | 0 | 6,700 | 0 | 0 | 0 |
| Other Non-Current Assets | 1,402,300 | 1,093,000 | 869,101 | 889,500 | 910,800 |
| TOTAL | $12,042,700 | $11,419,900 | $9,896,101 | $8,148,300 | $7,717,100 |
| Total Assets | $26,348,700 | $25,434,800 | $23,671,500 | $21,485,900 | $17,772,200 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 470,300 | 564,000 | 427,000 | 476,000 | 542,900 |
| Other current liabilities | 2,046,000 | 2,206,800 | 2,061,000 | 2,018,000 | 1,492,200 |
| TOTAL | $3,007,600 | $3,932,500 | $3,714,800 | $3,732,400 | $3,217,800 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,980,400 | 1,980,000 | 1,979,600 | 1,979,200 | 1,978,900 |
| Deferred Revenues | 491,300 | 442,000 | 507,800 | 520,000 | 464,900 |
| aiOther Non-Current Liabilities | 692,500 | 680,200 | 662,600 | 596,300 | 571,500 |
| TOTAL | $3,426,400 | $2,733,500 | $2,698,700 | $2,626,200 | $2,577,400 |
| Total Liabilities | $6,434,000 | $6,666,000 | $6,413,500 | $6,358,600 | $5,795,200 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 109,846 | 108,539 | 107,543 | 106,955 | 106,544 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 19,941,800 | 18,968,300 | 16,739,300 | 15,107,100 | 12,008,200 |
| Other shareholders' equity | -170,300 | -26,100 | 9,300 | 15,300 | 15,900 |
| TOTAL | $19,914,700 | $18,768,800 | $17,258,000 | $15,127,300 | $11,977,000 |
| Total Liabilities And Equity | $26,348,700 | $25,434,800 | $23,671,500 | $21,485,900 | $17,772,200 |